Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2011

Open Access 01-12-2011 | Research article

Static and dynamic mechanics of the murine lung after intratracheal bleomycin

Authors: Effrosyni D Manali, Charalampos Moschos, Christina Triantafillidou, Anastasia Kotanidou, Ioannis Psallidas, Sophia P Karabela, Charis Roussos, Spyridon Papiris, Apostolos Armaganidis, Georgios T Stathopoulos, Nikolaos A Maniatis

Published in: BMC Pulmonary Medicine | Issue 1/2011

Login to get access

Abstract

Background

Despite its widespread use in pulmonary fibrosis research, the bleomycin mouse model has not been thoroughly validated from a pulmonary functional standpoint using new technologies. Purpose of this study was to systematically assess the functional alterations induced in murine lungs by fibrogenic agent bleomycin and to compare the forced oscillation technique with quasi-static pressure-volume curves in mice following bleomycin exposure.

Methods

Single intratracheal injections of saline (50 μL) or bleomycin (2 mg/Kg in 50 μL saline) were administered to C57BL/6 (n = 40) and Balb/c (n = 32) mice. Injury/fibrosis score, tissue volume density (TVD), collagen content, airway resistance (R N ), tissue damping (G) and elastance coefficient (H), hysteresivity (η), and area of pressure-volume curve (PV-A) were determined after 7 and 21 days (inflammation and fibrosis stage, respectively). Statistical hypothesis testing was performed using one-way ANOVA with LSD post hoc tests.

Results

Both C57BL/6 and Balb/c mice developed weight loss and lung inflammation after bleomycin. However, only C57BL/6 mice displayed cachexia and fibrosis, evidenced by increased fibrosis score, TVD, and collagen. At day 7, PV-A increased significantly and G and H non-significantly in bleomycin-exposed C57BL/6 mice compared to saline controls and further increase in all parameters was documented at day 21. G and H, but not PV-A, correlated well with the presence of fibrosis based on histology, TVD and collagen. In Balb/c mice, no change in collagen content, histology score, TVD, H and G was noted following bleomycin exposure, yet PV-A increased significantly compared to saline controls.

Conclusions

Lung dysfunction in the bleomycin model is more pronounced during the fibrosis stage rather than the inflammation stage. Forced oscillation mechanics are accurate indicators of experimental bleomycin-induced lung fibrosis. Quasi-static PV-curves may be more sensitive than forced oscillations at detecting inflammation and fibrosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM: Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009, 33: 882-896. 10.1183/09031936.00152607.CrossRefPubMed Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM: Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009, 33: 882-896. 10.1183/09031936.00152607.CrossRefPubMed
2.
go back to reference Antoniou KM, Wells AU: Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol. 2008, 20: 686-691. 10.1097/BOR.0b013e3283126985.CrossRefPubMed Antoniou KM, Wells AU: Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol. 2008, 20: 686-691. 10.1097/BOR.0b013e3283126985.CrossRefPubMed
3.
go back to reference Maher TM, Wells AU, Laurent GJ: Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J. 2007, 30: 835-839. 10.1183/09031936.00069307.CrossRefPubMed Maher TM, Wells AU, Laurent GJ: Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J. 2007, 30: 835-839. 10.1183/09031936.00069307.CrossRefPubMed
4.
go back to reference Ebihara T, Venkatesan N, Tanaka R, Ludwig MS: Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects. Am J Respir Crit Care Med. 2000, 162: 1569-1576.CrossRefPubMed Ebihara T, Venkatesan N, Tanaka R, Ludwig MS: Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects. Am J Respir Crit Care Med. 2000, 162: 1569-1576.CrossRefPubMed
5.
go back to reference Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R: Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002, 83: 111-119. 10.1046/j.1365-2613.2002.00220.x.CrossRefPubMedPubMedCentral Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R: Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002, 83: 111-119. 10.1046/j.1365-2613.2002.00220.x.CrossRefPubMedPubMedCentral
6.
go back to reference Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG, Blackwell TS: Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med. 2005, 171: 899-907. 10.1164/rccm.200311-1535OC.CrossRefPubMed Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG, Blackwell TS: Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med. 2005, 171: 899-907. 10.1164/rccm.200311-1535OC.CrossRefPubMed
7.
go back to reference Pottier N, Chupin C, Defamie V, Cardinaud B, Sutherland R, Rios G, Gauthier F, Wolters PJ, Berthiaume Y, Barbry P, et al: Relationships between early inflammatory response to bleomycin and sensitivity to lung fibrosis: a role for dipeptidyl-peptidase I and tissue inhibitor of metalloproteinase-3?. Am J Respir Crit Care Med. 2007, 176: 1098-1107. 10.1164/rccm.200607-1051OC.CrossRefPubMed Pottier N, Chupin C, Defamie V, Cardinaud B, Sutherland R, Rios G, Gauthier F, Wolters PJ, Berthiaume Y, Barbry P, et al: Relationships between early inflammatory response to bleomycin and sensitivity to lung fibrosis: a role for dipeptidyl-peptidase I and tissue inhibitor of metalloproteinase-3?. Am J Respir Crit Care Med. 2007, 176: 1098-1107. 10.1164/rccm.200607-1051OC.CrossRefPubMed
8.
go back to reference Dolhnikoff M, Mauad T, Ludwig MS: Extracellular matrix and oscillatory mechanics of rat lung parenchyma in bleomycin-induced fibrosis. Am J Respir Crit Care Med. 1999, 160: 1750-1757.CrossRefPubMed Dolhnikoff M, Mauad T, Ludwig MS: Extracellular matrix and oscillatory mechanics of rat lung parenchyma in bleomycin-induced fibrosis. Am J Respir Crit Care Med. 1999, 160: 1750-1757.CrossRefPubMed
9.
go back to reference Card JW, Voltz JW, Carey MA, Bradbury JA, Degraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC: Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol. 2007, 37: 300-308. 10.1165/rcmb.2007-0057OC.CrossRefPubMedPubMedCentral Card JW, Voltz JW, Carey MA, Bradbury JA, Degraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC: Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol. 2007, 37: 300-308. 10.1165/rcmb.2007-0057OC.CrossRefPubMedPubMedCentral
10.
go back to reference Chua F, Gauldie J, Laurent GJ: Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005, 33: 9-13. 10.1165/rcmb.2005-0062TR.CrossRefPubMed Chua F, Gauldie J, Laurent GJ: Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005, 33: 9-13. 10.1165/rcmb.2005-0062TR.CrossRefPubMed
11.
go back to reference Gauldie J, Kolb M: Animal models of pulmonary fibrosis: how far from effective reality?. Am J Physiol Lung Cell Mol Physiol. 2008, 294: L151-CrossRefPubMed Gauldie J, Kolb M: Animal models of pulmonary fibrosis: how far from effective reality?. Am J Physiol Lung Cell Mol Physiol. 2008, 294: L151-CrossRefPubMed
12.
go back to reference Moeller A, Ask K, Warburton D, Gauldie J, Kolb M: The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int J Biochem Cell Biol. 2008, 40: 362-382. 10.1016/j.biocel.2007.08.011.CrossRefPubMed Moeller A, Ask K, Warburton D, Gauldie J, Kolb M: The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int J Biochem Cell Biol. 2008, 40: 362-382. 10.1016/j.biocel.2007.08.011.CrossRefPubMed
13.
go back to reference Goldstein RH, Lucey EC, Franzblau C, Snider GL: Failure of mechanical properties to parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis. 1979, 120: 67-73.PubMed Goldstein RH, Lucey EC, Franzblau C, Snider GL: Failure of mechanical properties to parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis. 1979, 120: 67-73.PubMed
14.
go back to reference Bates JH, Irvin CG: Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol. 2003, 94: 1297-1306.CrossRefPubMed Bates JH, Irvin CG: Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol. 2003, 94: 1297-1306.CrossRefPubMed
15.
go back to reference Gomes RF, Shen X, Ramchandani R, Tepper RS, Bates JH: Comparative respiratory system mechanics in rodents. J Appl Physiol. 2000, 89: 908-916.PubMed Gomes RF, Shen X, Ramchandani R, Tepper RS, Bates JH: Comparative respiratory system mechanics in rodents. J Appl Physiol. 2000, 89: 908-916.PubMed
16.
go back to reference Pinart M, Serrano-Mollar A, Negri EM, Cabrera R, Rocco PR, Romero PV: Inflammatory related changes in lung tissue mechanics after bleomycin-induced lung injury. Respir Physiol Neurobiol. 2008, 160: 196-203. 10.1016/j.resp.2007.09.012.CrossRefPubMed Pinart M, Serrano-Mollar A, Negri EM, Cabrera R, Rocco PR, Romero PV: Inflammatory related changes in lung tissue mechanics after bleomycin-induced lung injury. Respir Physiol Neurobiol. 2008, 160: 196-203. 10.1016/j.resp.2007.09.012.CrossRefPubMed
17.
go back to reference Hantos Z, Daroczy B, Suki B, Nagy S: Low-frequency respiratory mechanical impedance in the rat. J Appl Physiol. 1987, 63: 36-43.PubMed Hantos Z, Daroczy B, Suki B, Nagy S: Low-frequency respiratory mechanical impedance in the rat. J Appl Physiol. 1987, 63: 36-43.PubMed
18.
go back to reference Hantos Z, Daroczy B, Suki B, Nagy S, Debreczeni LA: Respiratory mechanical impedance in the rat. Acta Physiol Hung. 1987, 70: 289-296.PubMed Hantos Z, Daroczy B, Suki B, Nagy S, Debreczeni LA: Respiratory mechanical impedance in the rat. Acta Physiol Hung. 1987, 70: 289-296.PubMed
19.
go back to reference Cohen JC, Lundblad LK, Bates JH, Levitzky M, Larson JE: The "Goldilocks effect" in cystic fibrosis: identification of a lung phenotype in the cftr knockout and heterozygous mouse. BMC Genet. 2004, 5: 21-CrossRefPubMed Cohen JC, Lundblad LK, Bates JH, Levitzky M, Larson JE: The "Goldilocks effect" in cystic fibrosis: identification of a lung phenotype in the cftr knockout and heterozygous mouse. BMC Genet. 2004, 5: 21-CrossRefPubMed
20.
go back to reference Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C, Papapetropoulos A: Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. Am J Respir Crit Care Med. 2008, 177: 1314-1321. 10.1164/rccm.200708-1141OC.CrossRefPubMed Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K, Roussos C, Papapetropoulos A: Angiopoietin-1 protects against airway inflammation and hyperreactivity in asthma. Am J Respir Crit Care Med. 2008, 177: 1314-1321. 10.1164/rccm.200708-1141OC.CrossRefPubMed
21.
go back to reference Tomioka S, Bates JH, Irvin CG: Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs. forced oscillations. J Appl Physiol. 2002, 93: 263-270.CrossRefPubMed Tomioka S, Bates JH, Irvin CG: Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs. forced oscillations. J Appl Physiol. 2002, 93: 263-270.CrossRefPubMed
22.
go back to reference Haston CK, Amos CI, King TM, Travis EL: Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res. 1996, 56: 2596-2601.PubMed Haston CK, Amos CI, King TM, Travis EL: Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res. 1996, 56: 2596-2601.PubMed
23.
go back to reference Haston CK, Tomko TG, Godin N, Kerckhoff L, Hallett MT: Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J Med Genet. 2005, 42: 464-473. 10.1136/jmg.2004.027938.CrossRefPubMedPubMedCentral Haston CK, Tomko TG, Godin N, Kerckhoff L, Hallett MT: Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J Med Genet. 2005, 42: 464-473. 10.1136/jmg.2004.027938.CrossRefPubMedPubMedCentral
24.
go back to reference Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, King TM, Weil MM, Newman RA, Amos CI, et al: Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet. 2002, 11: 1855-1863. 10.1093/hmg/11.16.1855.CrossRefPubMed Haston CK, Wang M, Dejournett RE, Zhou X, Ni D, Gu X, King TM, Weil MM, Newman RA, Amos CI, et al: Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum Mol Genet. 2002, 11: 1855-1863. 10.1093/hmg/11.16.1855.CrossRefPubMed
25.
go back to reference Lewis CC, Yang JY, Huang X, Banerjee SK, Blackburn MR, Baluk P, McDonald DM, Blackwell TS, Nagabhushanam V, Peters W, et al: Disease-specific gene expression profiling in multiple models of lung disease. Am J Respir Crit Care Med. 2008, 177: 376-387.CrossRefPubMed Lewis CC, Yang JY, Huang X, Banerjee SK, Blackburn MR, Baluk P, McDonald DM, Blackwell TS, Nagabhushanam V, Peters W, et al: Disease-specific gene expression profiling in multiple models of lung disease. Am J Respir Crit Care Med. 2008, 177: 376-387.CrossRefPubMed
26.
go back to reference Tran PL, Weinbach J, Opolon P, Linares-Cruz G, Reynes JP, Gregoire A, Kremer E, Durand H, Perricaudet M: Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene. J Clin Invest. 1997, 99: 608-617. 10.1172/JCI119203.CrossRefPubMedPubMedCentral Tran PL, Weinbach J, Opolon P, Linares-Cruz G, Reynes JP, Gregoire A, Kremer E, Durand H, Perricaudet M: Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene. J Clin Invest. 1997, 99: 608-617. 10.1172/JCI119203.CrossRefPubMedPubMedCentral
27.
go back to reference Grimby G, Takishima T, Graham W, Macklem P, Mead J: Frequency dependence of flow resistance in patients with obstructive lung disease. J Clin Invest. 1968, 47: 1455-1465. 10.1172/JCI105837.CrossRefPubMedPubMedCentral Grimby G, Takishima T, Graham W, Macklem P, Mead J: Frequency dependence of flow resistance in patients with obstructive lung disease. J Clin Invest. 1968, 47: 1455-1465. 10.1172/JCI105837.CrossRefPubMedPubMedCentral
28.
go back to reference Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med. 2005, 171: 261-268.CrossRefPubMed Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med. 2005, 171: 261-268.CrossRefPubMed
29.
go back to reference Lemay AM, Haston CK: Bleomycin-induced pulmonary fibrosis susceptibility genes in AcB/BcA recombinant congenic mice. Physiol Genomics. 2005, 23: 54-61. 10.1152/physiolgenomics.00095.2005.CrossRefPubMed Lemay AM, Haston CK: Bleomycin-induced pulmonary fibrosis susceptibility genes in AcB/BcA recombinant congenic mice. Physiol Genomics. 2005, 23: 54-61. 10.1152/physiolgenomics.00095.2005.CrossRefPubMed
30.
go back to reference Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, Peschon JJ, Schmidts HL, Brody AR, Friedman M: Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol. 1999, 20 (4): 825-833.CrossRefPubMed Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, Peschon JJ, Schmidts HL, Brody AR, Friedman M: Upregulation of the p75 but not the p55 TNF-alpha receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol. 1999, 20 (4): 825-833.CrossRefPubMed
31.
go back to reference Schrier DJ, Kunkel RG, Phan SH: The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1983, 127 (1): 63-66.CrossRefPubMed Schrier DJ, Kunkel RG, Phan SH: The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis. 1983, 127 (1): 63-66.CrossRefPubMed
32.
go back to reference Wells AU, Behr J, Silver R: Outcome measures in the lung. Rheumatology (Oxford). 2008, 47 (Suppl 5): v48-50.CrossRef Wells AU, Behr J, Silver R: Outcome measures in the lung. Rheumatology (Oxford). 2008, 47 (Suppl 5): v48-50.CrossRef
33.
go back to reference Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA, Tilley SL, Koller BH: COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2006, 291 (2): L144-156. 10.1152/ajplung.00492.2005.CrossRefPubMed Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA, Tilley SL, Koller BH: COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2006, 291 (2): L144-156. 10.1152/ajplung.00492.2005.CrossRefPubMed
34.
go back to reference Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, Hoet PH, Verbeken E, Decramer M, Nemery B, et al: Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol. 2010, 42 (1): 96-104. 10.1165/rcmb.2008-0487OC.CrossRefPubMed Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, Hoet PH, Verbeken E, Decramer M, Nemery B, et al: Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol. 2010, 42 (1): 96-104. 10.1165/rcmb.2008-0487OC.CrossRefPubMed
35.
go back to reference Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J: A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res. 11 (1): 34- Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J: A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res. 11 (1): 34-
36.
go back to reference Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, Ferrans VJ: Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology. 1995, 98 (1-3): 163-175. 10.1016/0300-483X(94)02987-6.CrossRefPubMed Herman EH, Hasinoff BB, Zhang J, Raley LG, Zhang TM, Fukuda Y, Ferrans VJ: Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. Toxicology. 1995, 98 (1-3): 163-175. 10.1016/0300-483X(94)02987-6.CrossRefPubMed
37.
go back to reference Polosukhin VV, Stathopoulos GT, Lawson WE, Blackwell TS: Variability of interalveolar septal remodeling after bleomycin treatment in mice. Ultrastruct Pathol. 2005, 29 (1): 53-64. 10.1080/019131290882286.CrossRefPubMed Polosukhin VV, Stathopoulos GT, Lawson WE, Blackwell TS: Variability of interalveolar septal remodeling after bleomycin treatment in mice. Ultrastruct Pathol. 2005, 29 (1): 53-64. 10.1080/019131290882286.CrossRefPubMed
38.
go back to reference Bates JH, Davis GS, Majumdar A, Butnor KJ, Suki B: Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med. 2007, 176 (6): 617-623. 10.1164/rccm.200611-1739OC.CrossRefPubMedPubMedCentral Bates JH, Davis GS, Majumdar A, Butnor KJ, Suki B: Linking parenchymal disease progression to changes in lung mechanical function by percolation. Am J Respir Crit Care Med. 2007, 176 (6): 617-623. 10.1164/rccm.200611-1739OC.CrossRefPubMedPubMedCentral
39.
go back to reference Suki B, Bates JH: Extracellular matrix mechanics in lung parenchymal diseases. Respir Physiol Neurobiol. 2008, 163 (1-3): 33-43. 10.1016/j.resp.2008.03.015.CrossRefPubMedPubMedCentral Suki B, Bates JH: Extracellular matrix mechanics in lung parenchymal diseases. Respir Physiol Neurobiol. 2008, 163 (1-3): 33-43. 10.1016/j.resp.2008.03.015.CrossRefPubMedPubMedCentral
40.
go back to reference Bates JH: Point:Counterpoint: lung impedance measurements are/are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol. 2007, 103 (5): 1900-1901. 10.1152/japplphysiol.00369.2007. discussion 1904CrossRefPubMed Bates JH: Point:Counterpoint: lung impedance measurements are/are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol. 2007, 103 (5): 1900-1901. 10.1152/japplphysiol.00369.2007. discussion 1904CrossRefPubMed
41.
go back to reference Wagers S, Lundblad LK, Ekman M, Irvin CG, Bates JH: The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?. J Appl Physiol. 2004, 96 (6): 2019-2027. 10.1152/japplphysiol.00924.2003.CrossRefPubMed Wagers S, Lundblad LK, Ekman M, Irvin CG, Bates JH: The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?. J Appl Physiol. 2004, 96 (6): 2019-2027. 10.1152/japplphysiol.00924.2003.CrossRefPubMed
42.
go back to reference Mitzner W: Counterpoint: lung impedance measurements are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol. 2007, 103 (5): 1901-1903. 10.1152/japplphysiol.00369.2007a. discussion 1903-1904CrossRefPubMed Mitzner W: Counterpoint: lung impedance measurements are not more useful than simpler measurements of lung function in animal models of pulmonary disease. J Appl Physiol. 2007, 103 (5): 1901-1903. 10.1152/japplphysiol.00369.2007a. discussion 1903-1904CrossRefPubMed
43.
go back to reference Cavarra E, Carraro F, Fineschi S, Naldini A, Bartalesi B, Pucci A, Lungarella G: Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs. Am J Physiol Lung Cell Mol Physiol. 2004, 287 (6): L1186-1192. 10.1152/ajplung.00170.2004.CrossRefPubMed Cavarra E, Carraro F, Fineschi S, Naldini A, Bartalesi B, Pucci A, Lungarella G: Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs. Am J Physiol Lung Cell Mol Physiol. 2004, 287 (6): L1186-1192. 10.1152/ajplung.00170.2004.CrossRefPubMed
44.
go back to reference Nava S, Rubini F: Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax. 1999, 54 (5): 390-395. 10.1136/thx.54.5.390.CrossRefPubMedPubMedCentral Nava S, Rubini F: Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax. 1999, 54 (5): 390-395. 10.1136/thx.54.5.390.CrossRefPubMedPubMedCentral
Metadata
Title
Static and dynamic mechanics of the murine lung after intratracheal bleomycin
Authors
Effrosyni D Manali
Charalampos Moschos
Christina Triantafillidou
Anastasia Kotanidou
Ioannis Psallidas
Sophia P Karabela
Charis Roussos
Spyridon Papiris
Apostolos Armaganidis
Georgios T Stathopoulos
Nikolaos A Maniatis
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2011
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-11-33

Other articles of this Issue 1/2011

BMC Pulmonary Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.